UniQure: Accelerated Approval Plan With US FDA May Save Five Years
Gene Therapy AMT-130 Could Become First Huntington’s Therapy
UniQure said discussions with the FDA resulted in a path forward for seeking accelerated approval of its gene therapy AMT-130 in Huntington’s disease.
